DE60336027D1 - Impfstoffe auf mannoproteinfreier Beta-Glucan-Basis - Google Patents

Impfstoffe auf mannoproteinfreier Beta-Glucan-Basis

Info

Publication number
DE60336027D1
DE60336027D1 DE60336027T DE60336027T DE60336027D1 DE 60336027 D1 DE60336027 D1 DE 60336027D1 DE 60336027 T DE60336027 T DE 60336027T DE 60336027 T DE60336027 T DE 60336027T DE 60336027 D1 DE60336027 D1 DE 60336027D1
Authority
DE
Germany
Prior art keywords
glucan
antibodies
protective
presented
mannoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60336027T
Other languages
German (de)
English (en)
Inventor
Luciano Polonelli
Antonio Cassone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60336027D1 publication Critical patent/DE60336027D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE60336027T 2002-05-15 2003-05-15 Impfstoffe auf mannoproteinfreier Beta-Glucan-Basis Expired - Lifetime DE60336027D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0211118.5A GB0211118D0 (en) 2002-05-15 2002-05-15 Vaccines

Publications (1)

Publication Number Publication Date
DE60336027D1 true DE60336027D1 (de) 2011-03-24

Family

ID=9936711

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60320979T Expired - Lifetime DE60320979D1 (de) 2002-05-15 2003-05-15 Impfstoffe gegen Pilzen aus Beta-Glucan
DE60336027T Expired - Lifetime DE60336027D1 (de) 2002-05-15 2003-05-15 Impfstoffe auf mannoproteinfreier Beta-Glucan-Basis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60320979T Expired - Lifetime DE60320979D1 (de) 2002-05-15 2003-05-15 Impfstoffe gegen Pilzen aus Beta-Glucan

Country Status (14)

Country Link
US (4) US20050208079A1 (enExample)
EP (2) EP1891970B1 (enExample)
JP (3) JP5110767B2 (enExample)
AT (2) ATE497781T1 (enExample)
AU (1) AU2003241104A1 (enExample)
CA (2) CA2830619A1 (enExample)
CY (1) CY1108234T1 (enExample)
DE (2) DE60320979D1 (enExample)
DK (1) DK1506009T3 (enExample)
ES (1) ES2306871T3 (enExample)
GB (1) GB0211118D0 (enExample)
PT (1) PT1506009E (enExample)
SI (1) SI1506009T1 (enExample)
WO (1) WO2003097091A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2005098435A2 (en) * 2004-04-05 2005-10-20 Universite Bordeaux 2 Peptides and peptidomimetics binding to cd23
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
EP2201961B1 (en) 2005-06-27 2018-01-24 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
EP1984004A4 (en) * 2006-01-17 2010-03-03 Sloan Kettering Inst Cancer THE THERAPY REINFORCING GLUCAN
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2007127668A2 (en) * 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
AU2013203785B2 (en) * 2006-11-06 2016-11-17 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
ES2397186T3 (es) * 2006-11-06 2013-03-05 Whitehead Institute Composiciones inmunomoduladoras y métodos para su uso
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
JP4687644B2 (ja) 2006-12-22 2011-05-25 富士ゼロックス株式会社 画像処理装置、画像読取装置及び画像形成装置
CA2706620C (en) 2007-11-26 2018-02-27 Novartis Ag Conjugated beta-1,3-linked glucans
PT2227248E (pt) * 2007-11-26 2014-08-27 Novartis Ag Glucanos com adjuvante
CN102119332A (zh) 2008-04-29 2011-07-06 免疫刺激公司 免疫调节组合物及其使用方法
NZ591768A (en) 2008-09-18 2012-11-30 Novartis Ag Vaccine adjuvant combinations
NL1036661C2 (en) 2009-03-04 2010-09-07 Serrix B V Anti-fungal compounds & compositions.
BRPI1008984A2 (pt) * 2009-03-10 2016-07-05 Palmed Teva Ltd novas e distintas variedades de cogumelos basidiomycotas superiores, biomassa de cogumelo, biomassa micelial, extrato de um cogumelo, cultura micelial submersa pura de coprinus comatus, cultura micelial submersa pura de tremella mesentérica, b-glucano de baixo peso molecular solúvel em água 3,4 b-glucano linear insolúvel em água obtiodo a partir de tremella mesentérica, glucuronixilomanano obtido a partir de tremella mesentérica, suplemento alimentar, comida para animais, composição farmacêutica e composição agrícola.
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
RS57937B1 (sr) * 2010-05-14 2019-01-31 Alltech Inc Komponente ćelijskog zida kvasca i njihova detekcija
US20120177681A1 (en) 2010-09-01 2012-07-12 Manmohan Singh Formulation of immunopotentiators
US9618508B2 (en) 2010-12-14 2017-04-11 Glaxosmithkline Biologicals Sa Flow cytometry analysis of materials adsorbed to metal salts
TR201811280T4 (tr) 2011-03-02 2018-08-27 Glaxosmithkline Biologicals Sa Düşük antijen ve/ veya adjuvan dozları olan karma aşılar.
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
CN104080479B (zh) 2011-11-07 2019-11-05 葛兰素史密丝克莱恩生物有限公司 包括spr0096和spr2021抗原的运载体分子
EP2822586A1 (en) 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of streptococcus pneumoniae antigens
SI2822947T1 (sl) 2012-03-07 2016-10-28 Glaxosmithkline Biologicals S.A. Argininske soli TLR7 agonista
EP2822581A2 (en) 2012-03-08 2015-01-14 Novartis AG Adjuvanted formulations of dtp booster vaccines
AU2013257139B2 (en) * 2012-04-30 2018-02-22 Biothera, Inc. Beta-glucan immunotherapeutic methods
CN105188747A (zh) 2013-02-01 2015-12-23 葛兰素史密斯克莱生物公司 包含toll样受体激动剂的免疫组合物的皮内递送
CN103083663B (zh) * 2013-02-04 2014-12-10 江苏省农业科学院 一种免疫增强剂、灭活疫苗及其制备方法
WO2014158963A1 (en) * 2013-03-12 2014-10-02 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides
KR20160040556A (ko) 2013-07-11 2016-04-14 노파르티스 아게 미생물 트랜스글루타미나제를 사용한 리신-특이적 화학효소적 단백질 변형
AU2014357446B2 (en) * 2013-12-05 2020-05-07 Biothera, Inc. Beta-glucan assay methods
CN107427528B (zh) * 2015-01-26 2022-09-23 卡莱多生物科技有限公司 聚糖治疗剂和其相关方法
CN104771498A (zh) * 2015-03-13 2015-07-15 臧海阳 一种治疗热毒蕴结型痄腮的中药组合物
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
CN111684061B (zh) * 2018-01-19 2024-07-30 美天施生物科技有限两合公司 表达嵌合抗原受体的调节性t细胞
US11701417B2 (en) * 2019-03-27 2023-07-18 West Virginia University Vaccine formulation to protect against pertussis
WO2023002252A1 (en) 2021-07-21 2023-01-26 Bioatlantis Limited Composition comprising beta-glucans and alpha-fucans for improving gut health and animal performance and methods of making the same
EP4486388A1 (en) 2022-02-28 2025-01-08 Tridem Bioscience GmbH & Co KG A conjugate consisting of or comprising at least a ss-glucan or a mannan
AU2023223603A1 (en) 2022-02-28 2024-08-22 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466289B (sv) * 1984-09-19 1992-01-27 James Hoffman Makrofagstimulerande komposition jaemte foerfarande foer dess framstaellning
JPS6383012A (ja) * 1986-09-26 1988-04-13 Nonogawa Shoji:Kk 化粧料
WO1991003495A1 (en) * 1989-09-08 1991-03-21 Alpha Beta Technology, Inc. Method for producing soluble glucans
EP0471954A3 (en) * 1990-08-13 1993-03-03 American Cyanamid Company Immunogenic conjugates of nontoxic oligosaccharide derived from bordetella pertussis lipooligosaccharide
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
ES2231770T3 (es) * 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
CN1094288A (zh) * 1993-04-23 1994-11-02 福建省微生物研究所 利用红色诺卡氏菌制造细胞壁骨架粉末的方法
NO300692B1 (no) 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
US6309642B1 (en) * 1997-04-28 2001-10-30 The Research And Development Institute, Inc. Peptides which mimic candida carbohydrate epitopes and their use in a vaccine
AUPN166195A0 (en) * 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
JPH09309842A (ja) * 1996-05-20 1997-12-02 Kureha Chem Ind Co Ltd 新規な生理活性物質、その製造方法及び医薬組成物
AU760669B2 (en) * 1998-04-28 2003-05-22 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
JP4230635B2 (ja) 2000-02-29 2009-02-25 富士フイルム株式会社 デジタルカメラ

Also Published As

Publication number Publication date
WO2003097091A2 (en) 2003-11-27
US20110059120A1 (en) 2011-03-10
CA2485847A1 (en) 2003-11-27
JP2005535298A (ja) 2005-11-24
CA2485847C (en) 2013-12-31
JP5684758B2 (ja) 2015-03-18
HK1114335A1 (en) 2008-10-31
SI1506009T1 (sl) 2008-10-31
AU2003241104A1 (en) 2003-12-02
PT1506009E (pt) 2008-08-14
ES2306871T3 (es) 2008-11-16
JP2012224636A (ja) 2012-11-15
DE60320979D1 (de) 2008-06-26
US7824688B2 (en) 2010-11-02
ATE497781T1 (de) 2011-02-15
EP1506009B1 (en) 2008-05-14
EP1506009A2 (en) 2005-02-16
CY1108234T1 (el) 2014-02-12
DK1506009T3 (da) 2008-09-01
HK1069125A1 (en) 2005-05-13
US20050208079A1 (en) 2005-09-22
GB0211118D0 (en) 2002-06-26
US8679506B2 (en) 2014-03-25
ATE395080T1 (de) 2008-05-15
US20070141088A1 (en) 2007-06-21
WO2003097091A3 (en) 2004-03-04
CA2830619A1 (en) 2003-11-27
EP1891970B1 (en) 2011-02-09
US20130171187A1 (en) 2013-07-04
US8398990B2 (en) 2013-03-19
JP2010131017A (ja) 2010-06-17
JP5110767B2 (ja) 2012-12-26
EP1891970A1 (en) 2008-02-27

Similar Documents

Publication Publication Date Title
DE60336027D1 (de) Impfstoffe auf mannoproteinfreier Beta-Glucan-Basis
EP2266607A3 (en) Immunoconjugates for treating cancer
PL377146A1 (pl) Cytokiny ochronne dla tkanek do ochrony, odnowy i wzmacniania reaktywnych komórek, tkanek i narządów
MX368377B (es) Combinacion de brimonidina y timolol para uso oftalmico, topico.
DE60021059D1 (de) Hydrogelpartikel formulierungen
CA2378892A1 (en) Preserved pharmaceutical formulations
MXPA03007942A (es) Preparaciones de insulina exentas de zinc y con bajo contenido de zinc, que tienen una estabilidad mejorada.
WO2005000241A3 (en) Compositons and methods for topical administration
DE60036915D1 (de) Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
EP4295917A3 (en) Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
ATE270115T1 (de) Behandlung einer intrazelluläre infektion
WO2003039592A3 (de) Zelluläre impfstoffe mit adjuvanzien
EA200501828A1 (ru) Тканепротекторные цитокины с увеличенным терапевтическим окном для защиты, восстановления и стимулирования реагирующих клеток, тканей и органов
ATE273704T1 (de) Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung
TW200505437A (en) Composition possessing autonomic nerve function regulating action and use thereof
CA2438509A1 (en) Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria
WO2004006851A3 (en) Mycoplasma gallisepticum formulation
WO2003077885A3 (en) Free-base formulations of local anesthetics
NZ584942A (en) Injectable meclizine formulations and methods comprising a molar excess of a modified cyclodextrin
ID26929A (id) Fungisida
ATE238050T1 (de) 4-cyano-4-deformylsordarizin-derivate
HK40120055A (zh) 包含靶向claudin18.2的抗体-药物偶联物的制剂及其制备方法和用途
WO2004052331A3 (fr) Utilisation d'un extrait de miellat de coton comme ingredient acitif
EP0943339A3 (en) Method of preventing allograft rejection
PL338704A1 (en) Derivatives of 4-cyano-4-deformylsordarin